Zheng Quan Zhi Xing·2025-09-05 16:34Group 1 - The report outlines the sponsorship work conducted by China International Capital Corporation (CICC) for Norska (Beijing) Pharmaceutical Technology Co., Ltd, confirming timely review of company disclosure documents and adherence to regulations [1] - CICC has conducted monthly checks on the company's fundraising special account and confirmed that the progress of fundraising projects aligns with disclosed information [1] - The report indicates that there was one instance of litigation involving an amount of 179,898,176.00 yuan, with the case now concluded without significant adverse effects on the company's operations or financial status [1][3] Group 2 - CICC has identified issues related to internal controls over R&D investments, revenue recognition, and procurement management, leading to a written warning from the Shenzhen Stock Exchange [3] - The company has actively pursued corrective measures in response to the regulatory actions taken against it [3]